Orkos Capital

Pierre-Edouard Berion, the founder and Managing Partner, leads the investment committee. Before Orkos, he worked at Seventure Partners, a French venture firm with a focus on life sciences and digital technologies. His investment history spans early-stage science-driven companies and growth-equity rounds across Europe.

It functions as a third-party asset manager raising capital from external limited partners. The firm's origin is independent; it is not tied to a single family fortune or industrial group. This distinguishes it from French single-family offices that occasionally compete for the same growth-stage technology deals.

Orkos is stage-agnostic, with a mandate that extends from seed rounds to control buyouts. The firm can participate in pre-revenue startup financing as well as later-stage expansion and co-investment structures. This full-lifecycle approach is atypical for a European private equity firm of its scale.

Confirmed focus areas include enterprise software, artificial intelligence and machine learning, and digital health. The portfolio has historically weighted toward companies where technical or scientific defensibility creates barriers to entry — that includes biology-driven therapeutics and AI applications sold into regulated industries.

Sourcing relies heavily on Berion's network within the French deep-tech and venture ecosystem, built over two decades. The firm's Paris location places it near research institutions and startup incubators that generate significant deal flow in AI and life sciences. Co-investor relationships with other European GPs also produce shared deal access.

The firm's model is built on direct deals, co-investments, and special purpose vehicles alongside other general partners. There is no public indication that Orkos operates a fund-of-funds program. The disclosed strategy descriptions point exclusively toward principal investments in operating companies.

France and continental Europe form the core investment territory. Some portfolio companies have drawn cross-border co-investors from the United States or Asia, but the firm itself invests from its Paris base and does not maintain additional offices outside France.